TGTX vs. PTCT, DCPH, CCXI, SAGE, APLS, CTLT, ELAN, ROIV, INSM, and ASND
Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include PTC Therapeutics (PTCT), Deciphera Pharmaceuticals (DCPH), ChemoCentryx (CCXI), Sage Therapeutics (SAGE), Apellis Pharmaceuticals (APLS), Catalent (CTLT), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
TG Therapeutics (NASDAQ:TGTX) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, community ranking, earnings, risk, media sentiment, analyst recommendations and institutional ownership.
TG Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
TG Therapeutics has a net margin of 14.24% compared to PTC Therapeutics' net margin of -62.45%. TG Therapeutics' return on equity of 31.34% beat PTC Therapeutics' return on equity.
TG Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
TG Therapeutics received 110 more outperform votes than PTC Therapeutics when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 61.83% of users gave PTC Therapeutics an outperform vote.
In the previous week, PTC Therapeutics had 5 more articles in the media than TG Therapeutics. MarketBeat recorded 8 mentions for PTC Therapeutics and 3 mentions for TG Therapeutics. PTC Therapeutics' average media sentiment score of 0.87 beat TG Therapeutics' score of 0.62 indicating that PTC Therapeutics is being referred to more favorably in the news media.
TG Therapeutics presently has a consensus target price of $29.83, indicating a potential upside of 83.03%. PTC Therapeutics has a consensus target price of $35.67, indicating a potential downside of 1.91%. Given TG Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe TG Therapeutics is more favorable than PTC Therapeutics.
58.6% of TG Therapeutics shares are owned by institutional investors. 9.2% of TG Therapeutics shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
TG Therapeutics beats PTC Therapeutics on 15 of the 18 factors compared between the two stocks.
Get TG Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TG Therapeutics Competitors List
Related Companies and Tools
